Renal denervation in treatment-resistant hypertension: a reappraisal

Alexandre Persu; Yu Jin; Fadl Elmula M. Fadl Elmula; Jean Renkin; Aud Hoieggen; Sverre E. Kjeldsen; Jan A. Staessen

doi:10.1016/j.coph.2014.12.013

Renal denervation in treatment-resistant hypertension: a reappraisal

Alexandre Persu^*, Yu Jin, Fadl Elmula M. Fadl Elmula, Jean Renkin, Aud Hoieggen, Sverre E. Kjeldsen, Jan A. Staessen

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

The Symplicity HTN-1 and 2 studies proposed renal denervation (RDN) as an effective and safe approach to treat patients with resistant hypertension, and were followed by an unprecedented wave of enthusiasm. The announcement that Symplicity HTN-3 failed to meet its primary efficacy endpoint put an abrupt stop to these overoptimistic expectations. The use of a sound methodology was enough to see the typical 25-30 mmHg systolic blood pressure decrease observed after RDN melt down to

Original language	English
Pages (from-to)	48-52
Journal	Current Opinion in Pharmacology
Volume	21
DOIs	https://doi.org/10.1016/j.coph.2014.12.013
Publication status	Published - Apr 2015

Access to Document

10.1016/j.coph.2014.12.013

Cite this

@article{0f0b2659305d4aadb1f800c8a7ab8147,

title = "Renal denervation in treatment-resistant hypertension: a reappraisal",

abstract = "The Symplicity HTN-1 and 2 studies proposed renal denervation (RDN) as an effective and safe approach to treat patients with resistant hypertension, and were followed by an unprecedented wave of enthusiasm. The announcement that Symplicity HTN-3 failed to meet its primary efficacy endpoint put an abrupt stop to these overoptimistic expectations. The use of a sound methodology was enough to see the typical 25-30 mmHg systolic blood pressure decrease observed after RDN melt down to ",

author = "Alexandre Persu and Yu Jin and Elmula, {Fadl Elmula M. Fadl} and Jean Renkin and Aud Hoieggen and Kjeldsen, {Sverre E.} and Staessen, {Jan A.}",

year = "2015",

month = apr,

doi = "10.1016/j.coph.2014.12.013",

language = "English",

volume = "21",

pages = "48--52",

journal = "Current Opinion in Pharmacology",

issn = "1471-4892",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - Renal denervation in treatment-resistant hypertension: a reappraisal

AU - Persu, Alexandre

AU - Jin, Yu

AU - Elmula, Fadl Elmula M. Fadl

AU - Renkin, Jean

AU - Hoieggen, Aud

AU - Kjeldsen, Sverre E.

AU - Staessen, Jan A.

PY - 2015/4

Y1 - 2015/4

N2 - The Symplicity HTN-1 and 2 studies proposed renal denervation (RDN) as an effective and safe approach to treat patients with resistant hypertension, and were followed by an unprecedented wave of enthusiasm. The announcement that Symplicity HTN-3 failed to meet its primary efficacy endpoint put an abrupt stop to these overoptimistic expectations. The use of a sound methodology was enough to see the typical 25-30 mmHg systolic blood pressure decrease observed after RDN melt down to

AB - The Symplicity HTN-1 and 2 studies proposed renal denervation (RDN) as an effective and safe approach to treat patients with resistant hypertension, and were followed by an unprecedented wave of enthusiasm. The announcement that Symplicity HTN-3 failed to meet its primary efficacy endpoint put an abrupt stop to these overoptimistic expectations. The use of a sound methodology was enough to see the typical 25-30 mmHg systolic blood pressure decrease observed after RDN melt down to

U2 - 10.1016/j.coph.2014.12.013

DO - 10.1016/j.coph.2014.12.013

M3 - Article

C2 - 25601357

SN - 1471-4892

VL - 21

SP - 48

EP - 52

JO - Current Opinion in Pharmacology

JF - Current Opinion in Pharmacology

ER -

Renal denervation in treatment-resistant hypertension: a reappraisal

Abstract

Access to Document

Fingerprint

Cite this